Quinotolast sodium FR71021|cas:101193-62-8|西域试剂

Quinotolast sodium FR71021,98.12%

产品编号：Bellancom-U00027| CAS NO：101193-62-8| 分子式：C₁₇H₁₂N₆NaO₃| 分子量：371.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-U00027		￥5000.00	杭州北京（现货）
Bellancom-U00027		￥8500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Quinotolast sodium FR71021

产品介绍

Quinotolast sodium (浓度范围为 1-100 μg/mL) 抑制组胺，LTC₄ 和 PGD₂ 释放，这种作用具有浓度依赖性。

生物活性

Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC₄ and PGD₂ release in a concentration-dependent manner.

体外研究

Quinotolast inhibits the release of histamine and the generation of leukotriene (LT) C₄ and prostaglandin (PG) D₂ from dispersed human lung cells. Quinotolast (100 μg/mL) significantly inhibits PGD₂ and LTC₄ release. Quinotolast inhibits PGD₂ release by 100% and LTC₄ release by 54%. The inhibitory effect of Quinotolast on histamine release from dispersed lung cells is largely independent of the preincubation period, no tachyphylaxis being observed. Quinotolast shows a significant inhibition of inflammatory mediators from human dispersed lung cells. Quinotolast also shows strong inhibitory effects on histamine and peptide leukotrienes release from guinea pig lung fragments or mouse cultured mast cells. Quinotolast concentration-dependently inhibits pLTs release from cultured mast cells. The IC₅₀ value for Quinotolast is 0.72 μg/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Quinotolast potently inhibits such type I allergic reactions as passive cutaneous anaphylaxis (PCA) and anaphylactic bronchoconstriction in rats by both intravenous and oral dosing. When Quinotolast is given i.v. to rats, Quinotolast, dose-dependently inhibits PCA. The doses of Quinotolast required to inhibit the reaction by 50% (ED₅₀) is 0.0063 mg/kg. Given p.o., Quinotolast inhibits the reaction. ED₅₀ value for Quinotolast is 0.0081 mg/kg. Although almost complete inhibition is observed with Quinotolast at a dose of 0.32 mg/kg, its effect is slightly attenuated at a dose of 1 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 115 mg/mL (309.71 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6932 mL	13.4658 mL	26.9317 mL
5 mM	0.5386 mL	2.6932 mL	5.3863 mL
10 mM	0.2693 mL	1.3466 mL	2.6932 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 5.75 mg/mL (15.49 mM); Suspended solution; Need ultrasonic

此方案可获得 5.75 mg/mL (15.49 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 57.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 5.75 mg/mL (15.49 mM); Suspended solution; Need ultrasonic

此方案可获得 5.75 mg/mL (15.49 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 57.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明